A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme

NCT ID: NCT01115491

Last Updated: 2014-12-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-06-30
• Study Completion Date: 2012-07-31

Brief Summary

This is a Phase II, national, multicenter, open-label, non-comparative study to investigate the efficacy and safety of bevacizumab and temozolomide in patients with recurrent glioblastoma multiforme (GBM) after a first treatment failure. Patients will receive bevacizumab 10 mg/kg intravenously every two weeks until disease progression, consent withdrawal, or unacceptable toxicity. Anticipated time on study treatment is 12-24 months.

Conditions

Glioblastoma Multiforme

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Group Type: EXPERIMENTAL

bevacizumab [Avastin]

Intervention Type: DRUG

Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks

temozolomide

Intervention Type: DRUG

Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle

Interventions

bevacizumab [Avastin]

Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks

Intervention Type: DRUG

temozolomide

Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age >= 18 years
• Histological diagnosis of glioblastoma multiforme (GBM) documented by surgical resection or biopsy.
• They should be patients in a first relapse treated with radiotherapy and chemotherapy and chemotherapy based on temozolomide 150-200 mg/m2 on days 1 to 5 every 28 days (Stupp regimen) for at least three cycles. At least 4 weeks must have lapsed since previous chemotherapy and 3 months since the last dose of radiotherapy.
• Use of an effective contraceptive method by patients and their partners.
• Stable or decreasing corticosteroid dose for the five days prior to study entry
• Adequate hematological function
• Adequate liver function
• Adequate kidney function

Exclusion Criteria

• Signs of recent bleeding at the MRI of the brain. However, patients with clinically asymptomatic presence of hemosiderin, resolving bleeding changes related to surgery, and presence of punctate hemorrhage in the tumor will be allowed to participate in the study.
• Prior treatment with bevacizumab
• Poorly controlled arterial hypertension
• History of hypertensive crises or hypertensive encephalopathy
• New York Health Association (NYHA) Class II or higher congestive heart failure
• History of myocardial infarction or unstable angina pectoris within six months of study entry
• History of stroke or TIA within six months of study entry
• Significant vascular disease within six months of study entry
• History of hemoptysis > grade 2 according to the NCI CTC criteria within one month of study entry
• Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
• Major surgery, open biopsy, intracranial biopsy, ventriculoperitoneal shunt, or major traumatic lesion within 28 days of study entry.
• Core needle biopsy (excluding intracranial biopsy) or other minor surgery within seven days of randomization. Placement of a central vascular access device (CVAD) if performed in the two days prior to bevacizumab administration
• History of abdominal fistula or gastrointestinal perforation within six months of study entry
• History of intracranial abscess within six months of randomization
• Any prior malignant neoplasm treated with curative intent in the five years prior to study entry, except for adequately controlled limited basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix
• Patients with any other metabolic or psychological disease
• Hypersensitivity to products derived from Chinese hamster ovary cells or to other humanized or recombinant human antibodies

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hoffmann-La Roche

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Barcelona, Barcelona, Spain

Barcelona, Barcelona, Spain

Barcelona, Barcelona, Spain

Madrid, Madrid, Spain

Madrid, Madrid, Spain

Madrid, Madrid, Spain

Valencia, Valencia, Spain

Valencia, Valencia, Spain

Countries

Spain

Other Identifiers

2010-019051-21

Identifier Type: -

Identifier Source: secondary_id

ML25152

Identifier Type: -

Identifier Source: org_study_id